Kadcyla (ado-trastuzumab emtansine)

April 17, 2019

AstraZeneca Teams with Daiichi Sankyo to Speed Development of HER2-positive Advanced Breast Cancer Therapy

News

AstraZeneca is starting a collaboration with Daiichi Sankyo for the global production and commercialization of trastuzumab deruxtecan (DS-8201), a novel antibody-drug conjugate under clinical studies for the treatment of advanced HER2-positive ... Read more

April 10, 2017April 10, 2017

PB272-Kadcyla Combo May Benefit HER2-Positive Breast Cancer Patients, Study Finds

News

A combination of PB272 (neratinib) and Kadcyla (ado-trastuzumab emtansine) may benefit HER2-positive metastatic breast cancer patients who previously received chemotherapy and another combo treatment, a clinical trial indicates. Results of the FB-10 ... Read more